High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial (Q37886394)

24 August 2017

title

High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial (English)

1 reference

24 August 2017

1 reference

14

1 reference

Simone Mathoulin-Pélissier

24 August 2017

2

I Ray-Coquard

0 references

13

object named as

S Mathoulin-Pélissier

1 reference

24 August 2017

B Bui-Nguyen

1

1 reference

24 August 2017

C Chevreau

3

1 reference

24 August 2017

N Penel

4

1 reference

24 August 2017

J O Bay

5

1 reference

24 August 2017

J M Coindre

6

1 reference

24 August 2017

D Cupissol

7

1 reference

24 August 2017

A Italiano

8

1 reference

24 August 2017

F Bonichon

9

1 reference

24 August 2017

J P Lotz

10

1 reference

24 August 2017

A Thyss

11

1 reference

24 August 2017

M Jimenez

12

1 reference

24 August 2017

GSF-GETO French Sarcoma Group

15

1 reference

24 August 2017

publication date

7 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

23

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

777-784

1 reference

Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR282

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR282

1 reference

24 August 2017

1 reference